-
1.发明授权公开(公告)号：US12097242B2
公开(公告)日：2024-09-24
申请号：US17721569
申请日：2022-04-15
发明人： Gene M. Dubowchik , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
IPC分类号： A61K38/22 , A61K38/18 , C07K1/107 , C07K14/64 , A61K38/00 , A61K45/06 , A61K47/64 , A61P9/00
CPC分类号： A61K38/18 , A61K38/2221 , C07K1/1077 , C07K14/64 , A61K38/00 , A61K45/06 , A61K47/64 , A61P9/00
摘要： The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
-
公开(公告)号：US11364281B2
公开(公告)日：2022-06-21
申请号：US17198939
申请日：2021-03-11
发明人： Gene M. Dubowchik , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
IPC分类号： A61K38/22 , A61K38/18 , C07K14/64 , C07K1/107 , A61K38/00 , A61K47/64 , A61P9/00 , A61K45/06
摘要： The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
-
公开(公告)号：US20190256570A1
公开(公告)日：2019-08-22
申请号：US16287342
申请日：2019-02-27
发明人： Gene M. Dubowchik , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
摘要： The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
-
公开(公告)号：US20180222960A1
公开(公告)日：2018-08-09
申请号：US15891492
申请日：2018-02-08
发明人： Gene M. DUBOWCHIK , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
摘要： The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
-
公开(公告)号：US20220331402A1
公开(公告)日：2022-10-20
申请号：US17721569
申请日：2022-04-15
发明人： Gene M. Dubowchik , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
摘要： The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
-
公开(公告)号：US11224634B2
公开(公告)日：2022-01-18
申请号：US17198939
申请日：2021-03-11
发明人： Gene M. Dubowchik , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
IPC分类号： A61K38/22 , A61K38/18 , C07K14/64 , C07K1/107 , A61K38/00 , A61K47/64 , A61P9/00 , A61K45/06
摘要： The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
-
7.发明授权公开(公告)号：US11185570B2
公开(公告)日：2021-11-30
申请号：US16287342
申请日：2019-02-27
发明人： Gene M. Dubowchik , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
摘要： The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
-
公开(公告)号：US12097241B2
公开(公告)日：2024-09-24
申请号：US17573238
申请日：2022-01-11
发明人： Gene M. Dubowchik , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
IPC分类号： A61K38/18 , A61K38/22 , C07K1/107 , C07K14/64 , A61K38/00 , A61K45/06 , A61K47/64 , A61P9/00
CPC分类号： A61K38/18 , A61K38/2221 , C07K1/1077 , C07K14/64 , A61K38/00 , A61K45/06 , A61K47/64 , A61P9/00
摘要： The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
-
公开(公告)号：US20220211812A1
公开(公告)日：2022-07-07
申请号：US17573238
申请日：2022-01-11
发明人： Gene M. Dubowchik , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
摘要： The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
-
公开(公告)号：US20210196791A1
公开(公告)日：2021-07-01
申请号：US17198939
申请日：2021-03-11
发明人： Gene M. Dubowchik , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
摘要： The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.029 秒)
